S

St. Joseph's Health Care London | Ivey Eye Institute

Research site

(Unclaimed)

Location

268 Grosvenor Street Room B1-108, London, Ontario, Canada

Site insights

Top conditions

Top treatments

Ranibizumab

LX211

VX-121

APL-2

Faricimab

Pegcetacoplan

Bevasiranib

GSK3326595

Simufilam

Bimatoprost

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 45 total trials

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in pa...

Active, not recruiting

Cystic Fibrosis

Drug: VX-121/TEZ/D-IVA

A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema (Meerkat)

This study will assess the efficacy and safety of vamikibart in participants with uveitic macular edema.

Active, not recruiting

Uveitic Macular Edema

Other: Sham

Drug: Vamikibart

An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD (GALE)

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with g...

Active, not recruiting

Geographic Atrophy Secondary to Age-related Macular Degeneration

Drug: PEGCETACOPLAN (APL-2)

Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) w...

Active, not recruiting

Age-Related Macular Degeneration

Geographic Atrophy

Drug: avacincaptad pegol

Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease (REFOCUS-ALZ)

A 76-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 76 we...

Active, not recruiting

Alzheimer Disease

Drug: Placebo

Drug: Simufilam